SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System | Optometry Times - Clinical News

Published on January 24, 2026
The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Continue reading on website
Other news

Pilocarpine 0.4%: Significant decrease in pupillary diameter in presbyopic patients | Optometry Times - Clinical News

January 23, 2026
Lens thickness and ciliary muscle are not affected by low-dose pilocarpine.

Tirzepatide Unlikely to Exacerbate DR in First Year of Treatment

January 26, 2026
Tirzepatide, recently FDA-approved for weight loss, offers substantial metabolic benefits and may be useful for patients with DR. Photo: Eli Lilly. Click image to enlarge. The popular drug tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown great benefits in glycemic control, weight loss an